Cell death-based treatment of lung adenocarcinoma.

Denisenko TV, Budkevich IN, Zhivotovsky B. · 2018

Read Cell death-based treatment of lung adenocarcinoma. by Denisenko TV, Budkevich IN, Zhivotovsky B. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5833343.txt.

Introduction

Denisenko, Budkevich, and Zhivotovsky review treatments that kill lung adenocarcinoma by forcing cell death. Their review appeared in Cell Death & Disease. This cancer is the commonest form of lung cancer. It is often found late and resists standard chemo and radiation.

The authors map the driver mutations behind it, such as KRAS, EGFR, and ALK fusions. They then survey targeted drugs built on those faults. A full section weighs how each therapy triggers cell death. Resistance is the thread throughout. Combined attacks on several pathways, they argue, beat single-drug strikes.

Catalog record

CREATORDenisenko TV, Budkevich IN, Zhivotovsky B.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE78 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5833343

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cell death-based treatment of lung adenocarcinoma By Tatiana V. Denisenko, Inna N. Budkevich, Boris Zhivotovsky Published in: Cell Death & Disease DOI: 10.1038/s41419-017-0063-y ABSTRACT The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of all lung cancer cases. In spite of achievements in understanding the pathogenesis of this disease and the development of new approaches in its treatment, unfortunately, lung ADC is still one of the most aggressive and rapidly fatal tumor types with overall survival less than 5 years. Lung ADC is often diagnosed at advanced stages involving disseminated metastatic tumors. This is particularly important for the successful development of new approaches in cancer therapy. The high resistance of lung ADC to conventional radiotherapies and chemotherapies represents a major challenge for treatment effectiveness. Here we discuss recent advances in understanding the molecular pathways driving tumor progression and related targeted therapies in lung ADCs. In addition, the cell death mechanisms induced by different treatment strategies and their contribution to therapy resistance are analyzed. The focus is on approaches to overcoming drug resistance in order to improve future treatment decisions. FACTS Lung adenocarcinoma is one of the most aggressive and rapidly fatal tumor types.Resistance of lung adenocarcinomas to conventional radio- and chemotherapies represents a major challenge for treatment effectiveness.Combined therapies overcome resistance and are more effective than drugs targeting only one specific protein or pathway. OPEN QUESTIONS What is the role of driving mutations in targeting therapy for lung adenocarcinoma?What should be done to improve the outcome of patients with tumors harboring specific alterations?Is crosstalk between different cell death modalities significant in combating lung adenocarcinoma?How can the resistance of lung adenocarcinoma to therapy be overcome? INTRODUCTION Cancer comprises a highly heterogeneous and complex set of diseases associated with a variety of genetic and epigenetic aberrations. The “hallmarks of cancer” involve a set of cellular traits essential for malignant transformation and tumor maintenance. Among these are sustained proliferative signaling, induced angiogenesis, activation of invasion and metastasis, resistance to cell death, ability to escape immunological surveillance, and various others1,2. Genetic intra-tumor heterogeneity also can contribute to treatment failure and drug resistance. Despite extensive research, the intrinsic and acquired resistance of tumors to drug treatment remains a fundamental challenge in improving patient’ outcomes. Lung cancer (LC) is the leading cause of cancer-related mortality3. Based on histology, LC is divided into two main subtypes: small cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), accounting for 15 and 85% of all cases, respectively4. NSCLC is further classified into three types: squamous-cell carcinoma, adenocarcinoma, and large-cell carcinoma. Squamous-cell carcinoma comprises 25–30% of all LC cases. It arises from early versions of squamous cells in the airway epithelial cells in the bronchial tubes in the center of the lungs. The most common type of LC is adenocarcinoma (ADC), which comprises around 40% of all LC. Lung ADCs develop from small airway epithelial, type II alveolar cells, which secrete mucus and other substances5,6. Large-cell (undifferentiated) carcinoma accounts for 5–10% of LC. This type of carcinoma shows no evidence of squamous or glandular maturation and as a result is often diagnosed by default through the exclusion of other possibilities7. The discovery of mutated oncogenes, which encode activated signaling molecules that drive cellular proliferation and promote tumor growth, has now led to the development of more effective and less toxic targeted drugs for LC patients. However, similar to conventional chemotherapies, these new-targeted drugs also have a propensity to fail due to the development of resistance. Gene mutations and focal amplification are genetic changes that modulate the sensitivity of tumors to the induction of cell death, and, therefore, differences in treatment sensitivity may depend on the susceptibility of LC cells, in general, and lung ADC cells, in particular, to undergo cell death8. Here we discuss recent advances in understanding the molecular pathways driving tumor progression and related targeted therapies in lung ADCs. In addition, the cell death mechanisms induced by different treatment strategies and their contribution to therapy resistance are analyzed. The focus is on the approaches to overcoming drug resistance in order to improve future treatment decisions. DRIVING MUTATIONS Lung ADCs commonly contain a heterogeneous mixture of histological growth patterns, classified as “mixed type”9. Although histological features and marker expression remain the basis of clinical diagnosis, recent advances in sequencing technologies have led to an understanding of tumor heterogeneity and have allowed the further subdivision of lung ADC into molecular subsets according to a classification based on so-called driver mutations. These mutations represent molecular alterations essential for tumor initiation and growth. They can often be detected in genes that control cellular proliferation and survival10,11. Thus, tumors might rely on the expression of these single-mutant oncogenes to promote tumor growth and survival, also known as the concept of oncogene addiction12,13. As tumor cells depend on the aberrant activity of a specific mutated gene or pathway for survival and proliferation, their inactivation is generally sufficient to induce growth arrest and/or cell death14. An interesting hypothesis has been proposed to explain the phenomenon of oncogenic addiction. According to this hypothesis, the apoptotic response observed in tumors in the case of acute disruption of an oncogene product results from differential decay of several pro-survival and pro-apoptotic signals emanating from the oncoproteins15. The disturbance in the balance between pro-apoptotic and pro-survival signals could trigger oncogenic shock, which eventually might drive tumor cell death15,16. The first actionable mutation detected in lung ADC was mutation in epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine kinase (RTK) that represents either somatic mutation deletion in exon 19 or L858R point mutation (Fig. 1)15,17. EGFR mutations near the ATP cleft of the tyrosine kinase (TK) domain result in increased receptor activation and act as oncogenic drivers. Binding with ligands (EGF and TGF-α) leads to conformational changes in EGFR and homodimerization or hetero-dimerization with other human epidermal growth factor receptor (HER) family members. There is subsequent auto-phosphorylation of the cytoplasmic TK domain with the help of adapter proteins (e.g., SHC and GRB-2), triggering downstream signaling pathways: (1) the rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MAPK) pathway; (2) the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway; (3) the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway. This stimulates mitosis, leading to cell proliferation and inhibition of apoptosis18,19. These pathways are crucial for normal cell growth. EGFR also serves as a stimulus for cancer growth.Fig. 1The EGFR-TKI resistance mechanisms and related targeted therapies in lung ADCThe resistance to the EGFR-TKI involves activation of several pathways. One of the mechanisms depends on the appearance of secondary mutations in EGFR, such as Thr790Met, L858R or deletion of exon 19. Another one includes activations of bypass signaling pathways such as PI3CA, MET, ERK, HER2 or AXL. Low mRNA level or polymorphism of pro-apoptotic protein Bim could also mediate intrinsic resistance of lung ADC to EGFR inhibitors. Alternatively, autophagy stimulation might sustain resistance to the RTK inhibitors (erlotinib and gefitinib) in these tumors. The inhibition of autophagy with chloroquine could accelerate RTKI-induced apoptosis and overcome resistance of lung ADC cells. For more detail, see the text Several types of activating mutations are known to occur in EGFR in NSCLC: Class I exon 19 in-frame deletions (44% of all EGFR

Read the complete text